Danaher is projected to report Q3 2026 revenue of $6.56 billion and adjusted EPS of $1.92, while shares trade at $229.04, slightly below the $235.41 average analyst target. The central narrative for this report is the recovery trajectory of the Biotechnology segment, specifically the realization of over $100 million in bioprocessing shipments that were delayed from the second quarter.
Investors are closely monitoring "core revenue growth excluding respiratory testing," which is expected to accelerate to approximately 5% as customer inventory destocking in biopharma reaches an inflection point. Management's commentary on China demand and the Masimo integration will be critical for validating the recently raised full-year 2026 earnings guidance.